VICTORIA, BRITISH COLUMBIA–(Marketwire – July 16, 2010) – Vigil Health Solutions Inc. (TSX VENTURE:VGL)(“Vigil”) today announced that it has entered into an aggregate $200,000 loan agreement with British Columbia Discovery Fund (VCC) Inc. and GrowthPoint Capital Corp. The loan is secured by all of Vigil’s property and is due and payable on December 31, 2010. The loan is convertible at the option of the lenders into Vigil’s common shares at a rate of one common share for each $0.10 of indebtedness ($0.20 if Vigil’s proposed consolidation announced below occurs). Any common shares issued on conversion of the loan will be subject to a four month hold period from today’s date. The obligations of Vigil and the lenders under the loan agreement are conditional upon receipt of acceptance by the TSX Venture Exchange of the loan.

Vigil will seek shareholder approval at its Annual General and Special Meeting of shareholders to be held on August 24, 2010, to consolidate its common shares at a ratio of one new share for each twenty outstanding common shares. In order to be effective, the consolidation resolution must be approved by at least three-quarters of the shareholder votes cast at the meeting and be accepted by the TSX Venture Exchange. The purpose of the share consolidation is to facilitate future financings and strategic initiatives by Vigil. Vigil currently has 100,046,135 common shares outstanding. If the consolidation is approved, Vigil will have approximately 5,002,306 common shares outstanding. Vigil’s name will not be changed in connection with the proposed consolidation.

MUNDELEIN, IL–(Marketwire – July 16, 2010) – Medline Industries, Inc., the company who produced the original Pink Glove Dance, is looking for breast cancer survivors in the San Francisco area who want to be part of the next Pink Glove Dance video. The original video has become an internet sensation, generating almost 11 million views on YouTube since its release last November. The video features healthcare workers at Providence St. Vincent Medical Center in Portland, Ore. dancing while wearing pink gloves.

When and where will it be?
Filming will take place Saturday, July 24^th at 3:00 p.m. in the big field just east of Fort Point Pier, with the Golden Gate Bridge in the background.

What are the qualifications to participate?
Participants need to be breast cancer survivors and willing to dance wearing pink gloves. No special dancing skills required. A choreographer will be there to teach simple routines.

How long will it take?
Approximately two hours.

How do I sign up?
Details of the video shoot and registration can be found online at www.pinkglovedance.com/sign-up.
Although participants can just show up on the day of the event, participants are encouraged to register online. 

Details of the day, and any weather updates, will be posted on www.pinkglovedance.com.

Why is this video being made?
The first video was created to help spread the word about breast cancer awareness and the importance of the healthcare worker who takes care of breast cancer patients. It was so successful and generated so much positive attention that hospitals around the country called to see if they could be part of the next video. So the idea of a sequel was developed that not only included hospital workers but breast cancer survivors too. 

Why pink exam gloves?
As a way to extend Medline’s breast cancer awareness campaign, the company developed a pink glove called Generation Pink™. Gloves are also the first point of contact between the healthcare worker and the patient. And, the fact the glove is pink, Medline hoped would get people talking about breast cancer. When the gloves were launched in October, Medline committed to donating $1 of every case purchased to the National Breast Cancer Foundation to fund mammograms for individuals who cannot afford them. In the past five years, Medline has donated almost $500,000 to the National Breast Cancer Foundation. 

MADISON, WI–(Marketwire – July 16, 2010) – TomoTherapy Incorporated (NASDAQ: TOMO) maker of advanced, integrated radiation therapy solutions for cancer care, today announced that James Cook University Hospital (JCUH) in Middlesbrough, England began treating cancer patients with the TomoTherapy^® Hi·Art^® treatment system last month. The TomoTherapy treatment system, which enables delivery of state-of-the-art CT image-guided intensity modulated radiotherapy (IG-IMRT), reinforces the hospital’s leadership in cancer care for the people of the North East of England. 

Among the first people to be treated was a 55-year-old female patient from Middlesbrough with breast cancer and an unusual chest anatomy. “We could not have treated this woman on a conventional linear accelerator treatment machine, nor with surgery, so it’s extremely satisfying to know we can now offer this quality of treatment to a wider range of patients,” said Karen Pilling, the superintendent radiographer in charge of the TomoTherapy system at JCUH. “The start-up from training through to treating our first patients has been very smooth and easy, and we are benefiting from the reduced set-up time required by the TomoTherapy treatment system. With integrated CT image guidance we are able to see the treatment plan with isodose contours overlaid onto the daily CT images, giving us extra reassurance that the treatment is the most accurate possible.” 

The TomoTherapy treatment system delivers radiation therapy in continuous helical rotations around the patient’s body. By enabling precise IMRT, the system allows clinicians to conform treatment to the shape of the tumor while helping to reduce radiation exposure to surrounding healthy tissue and critical structures. In addition, TomoTherapy technology allows the radiotherapy staff to directly CT image the soft tissues and tumour immediately prior to treatment, and make any necessary adjustments, thereby ensuring greater accuracy for high precision techniques where internal anatomy might change throughout the course of treatment.

Dr. Peter Dunlop, clinical oncologist and clinical director of the James Cook oncology service, outlining his reasons for choosing the TomoTherapy platform stated, “We felt it was extremely important to have fully integrated image guidance and intensity modulation, and we believe TomoTherapy provides that most effectively. It produces the best conformality available. The design of the system is such that there are no junctions, no matching fields, minimized risk of dose calculation mistakes, no uncontrolled hotspots, no gantry collisions and no more electron mode errors. For patients, the megavoltage CT (MVCT) set-ups ensure that we are accurately targeting their tumours. We have found the operation is smooth and treatments are comfortable for patients because they are often quicker than with conventional IMRT, especially in complex head and neck cases.”

Christopher Walker, head of Radiotherapy Physics at James Cook, responsible for all technical and medical physics aspects of this advanced technology, stated, “Procurement of the TomoTherapy system has provided Middlesbrough with an ‘off the shelf’ technical solution to the challenges faced in delivering high quality radiotherapy. The TomoTherapy solution has allowed us to leapfrog to a position of excellence in cancer care in the U.K. The system has a small physical footprint coupled with a reduced radiation shielding requirement compared to conventional machines. We were able to install it in a pre-existing treatment room, which was considered obsolete by present day conventional radiotherapy standards. As a result, TomoTherapy technology has allowed us to provide additional treatment capacity without the need for an expensive new build whilst maximising the efficiency of the existing facility. Installation and acceptance testing passed quickly and seamlessly allowing the physics team to concentrate on the clinical commissioning process. This process was reduced to a relatively simple validation exercise as all the beam data required for patient treatment planning was already pre-loaded in to the dedicated planning computer. The collaborative approach presented by TomoTherapy has allowed us to rapidly introduce advanced treatment methodologies in a safe and controlled way. The whole process was greatly enhanced by the support and training offered to us both by TomoTherapy and Oncology Systems Limited.”

James Cook University Hospital, as a publicly funded National Health Service hospital, has firmly embraced this radiotherapy technology as the most advanced treatment in its arsenal and as a cost-effective approach for treating technically complex cases.

“At an extremely difficult economic time, particularly within the public sector, James Cook has above all, upheld its belief in the unsurpassed quality of treatment brought by TomoTherapy,” says Julie Mead, director and clinical advisor at Oncology Systems Ltd. “The whole oncology team, with support from the Trust Management, has worked hard to secure this new technology for the people of the North East of England. Now with its TomoTherapy system in place, James Cook has become a leader in the UK NHS with the ability to offer world class radiotherapy for its patients.”

TomoTherapy technology is developed and manufactured by TomoTherapy Inc. and is supplied in the U.K. by Oncology Systems Limited, based in Shrewsbury, England.

About James Cook University Hospital 
Based in the north east of England, JCUH is an NHS Foundation Trust and large district general hospital. The hospital was opened in October 2003 and has a capacity of 1,007 beds. It incorporates the full range of all acute and elective medical and surgical specialties including cardiac surgery, cardiology, renal medicine / haemodialysis, neurosurgery, vascular surgery and the regional spinal injuries unit. The radiotherapy and oncology service delivers an integrated service to a population of approximately one million, extending through Teesside, South Durham and North Yorkshire.

About Oncology Systems Limited 
Oncology Systems Limited (OSL), is a privately owned limited company based in Shrewsbury, England. OSL is an exclusive supplier of radiation therapy technology to the UK and Ireland. It distributes TomoTherapy^® cancer treatment technology to the UK’s NHS and private radiotherapy facilities, and to both public and private providers in the Republic of Ireland.

About TomoTherapy Incorporated 
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art^® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD^™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

BEVERLY HILLS, CA–(Marketwire – July 16, 2010) –  After the completion of one quarter since the acquisition of the Bella Vita Clinic in the Greater Toronto Area (GTA), Therma-Med Inc. (PINKSHEETS: THRA) is pleased with the steady progress that has been evident throughout the transition period and are optimistic about the continued growth of the clinic. The clinic is picking up steam as we move into the second quarter of ownership, it has been established that the Bella Vita clinic is a revenue generating acquisition, and is an active contributor to Therma-Med Inc.’s overall growth plan. The clinic is actively in the process of hiring an additional Chiropractor, Massage Therapist and Naturopathic Doctor to its existing staff, in order to position themselves at the forefront of wellness centers in the area. The additional support will allow the clinic to operate at extended hours, conveniently catering to all patients, and the added services available will certainly attract patients that are searching for a “1 stop wellness retreat.”

The Therma-Med Inc. business model of implementing support services and making key revenue producing acquisitions is without question showing results on a small scale as is demonstrated with the Bella Vita Clinic. While taking these steps to grow operations at this recently acquired clinic, plans continue to move forward in accordance with the company’s business plan of targeting, researching, and implementing Thermal Imaging, medical support services and nutraceutical sales at additional key revenue generating clinics across North America.

About Therma-Med Inc.:
Therma-Med Inc. provides alternative medicinal procedures, premium nutritional supplements, medicinal products and current medical support services by making them available to patients through their clinics and online through e-commerce purchasing applications. Therma-Med Inc., through highly specialized Thermal Imaging and breakthrough alternative procedure clinics, is poised to become a healthcare industry leading company, providing the alternative medicine approach to good health, as well as providing patients with an adjunctive diagnostic procedure that effectively pursues and exposes the benefits of early detection and prevention of various medical conditions. Therma-Med Inc. utilizes thermal imaging systems that incorporate state-of-the-art infrared technologies and proprietary software to accurately and cost-effectively measure physiological changes in the human body, allowing patients of all walks of life access to a proactive form of maintaining good health and quality of life through early detection and prevention.

Cautionary Statement Regarding Forward-Looking Information:
Except for statements of historical fact relating to the Corporation, certain information contained herein constitutes forward-looking statements. Forward-looking statements are frequently characterized by words such as “potential,” “estimate,” “plan,” “expect,” “project,” “intend,” “believe,” “anticipate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Corporation undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change. The reader is cautioned not to place undue reliance on forward-looking statements.

IRVINE, CA–(Marketwire – July 15, 2010) –  Sun Healthcare Group, Inc. (NASDAQ: SUNH) invites investors to listen to a conference call with Sun’s senior management on Thursday, July 29, 2010, at 10 a.m. Pacific / 1 p.m. Eastern to discuss the Company’s earnings for the second quarter of 2010.

To listen to the conference call, dial (888) 437-9315 and refer to Sun Healthcare Group. A recording of the call will be available from 4 p.m. Eastern on July 29, 2010, until midnight Eastern on Aug. 30, 2010, by calling (888) 203-1112 and using access code 1833674.

About Sun Healthcare Group, Inc.

Sun Healthcare Group, Inc.’s (NASDAQ: SUNH) subsidiaries provide nursing, rehabilitative and related specialty healthcare services principally to the senior population in the United States. Sun’s core business is providing inpatient services, primarily through 166 skilled nursing centers, 16 combined skilled nursing, assisted and independent living centers, 10 assisted living centers, two independent living centers and eight mental health centers. On a consolidated basis, Sun has annual revenues of $1.9 billion and approximately 30,000 employees in 46 states. At March 31, 2010, SunBridge centers had 23,205 licensed beds located in 25 states, of which 22,423 were available for occupancy. Sun also provides rehabilitation therapy services to affiliated and non-affiliated centers through its SunDance subsidiary, medical staffing services through its CareerStaff Unlimited subsidiary and hospice services through its SolAmor subsidiary.

COLUMBIA, SC–(Marketwire – July 15, 2010) –  BDI Pharma, Inc. (BDI), the nation’s fastest growing national distributor of biotech therapies, announced that, in spite of the uncertainty of the nation’s current economic climate, Sales Revenues continued to rise during the first two (2) fiscal quarters of 2010. This expansion of business represented an increase of fifteen percent (15%) above that for the same period in 2009 and exceeded the company’s forecasted growth for the first six (6) months of the year. The Specialty Biopharmaceutical class of products, primarily in the clinical areas of Oncology and Infectious Disease, served as the primary driver for Sales Revenue during this period. Also notable were gains within the Protein Biotherapeutics class, specific to the Hemophilia and Hyper-Immune product lines.

In addition, BDI Pharma realized significant growth in staffing through new hires during Q2 2010. Over the past ninety (90) days, the size of the company’s Biopharmaceutical Sales Staff grew by twenty percent (20%). The company also experienced growth within the BDI Promotions Division (the company’s Advertising and Promotional Division), as well as the Corporate Customer Service Division and established a new specialty sales division during the past quarter.

“Growth, at BDI Pharma, is not just an objective, it is an expectation and, as such, it is something for which we plan and prepare,” said William A. Shirey, III, Executive VP. “The key to BDI Pharma’s growth can be found in our commitment to incorporate a relatively simple matter — the strategic allocation of corporate resources — and to merge it with something far more difficult — the actual expense of those resources in a conscientious manner. Many companies adopt the former, but ultimately bend in response to market pressure and lose their will to integrate the latter. At BDI Pharma, we apply both with equal veracity as we strive to supply substantial, quantifiable value to our customers and manufacturing trade partners, alike.”

About BDI Pharma, Inc.

Since 1995, BDI Pharma, Inc. (formerly known as Blood Diagnostics, Inc.) has built an exceptional reputation as the industry trusted source for products and service. The company has exhibited an exemplary track record providing an unparalleled level of customer service, market data and product integrity to both its customer base and trade partners. Such commitment to the product channel has earned BDI recognition as “ADR,” or Authorized Distributor of Record, for the manufacturers it represents. BDI’s specialty pharmaceutical focus is evident in its commitment to biotherapeutics, chemotherapies, vaccines and plasma protein therapies, including albumin, IVIG, coagulation factors, high-titer immune globulins, and injectables. 

BDI Pharma defines its customer-centric approach to serving the nation’s healthcare community through innovative inventory supply solutions, unparalleled customer service, extensive product knowledge, 24/7 emergency availability and urgent need delivery. An open-access resource for reference material, educational literature, market data and online ordering, BDI Pharma’s home web page www.bdipharma.com has become an industry renowned point of reference. Proprietary programs for product consignment (www.consignadvantage.com), influenza vaccine pre-booking (www.securiflu.com), vaccine ordering (www.securivax.com) and purchasing/reward programs (www.qoreprogram.com and www.securigam.com) round out a family of solutions tailored to the needs of the healthcare community at large.

SAN FRANCISCO, CA–(Marketwire – July 15, 2010) –  With the innovative use of several emerging technologies, San Francisco-based digital healthcare agency Eveo made a big impression at the 2010 ASCO trade show. The 46th Annual meeting of the American Society of Clinical Oncology (ASCO) was held in Chicago, June 4-8, 2010, where more than 30,000 oncology specialists from around the world gathered to discuss the latest innovations in research, quality, practice and technology in cancer. Eveo (www.eveo.com) partnered with marketers to create customized, engaging programs that improved the overall quality of customer interactions and led to a dramatic increase in booth traffic.

Eveo’s Stereoscopic 3D Animation Video was viewed by over 1,000 participants at ASCO. In addition, the multi-touch technology and “Build a Patient” program were showstoppers as they deepened customer engagement and improved retention. Eveo also released several new applications for the iPhone and iPad that enabled health care providers to stay connected with their customers in a whole new way. “We knew the technologies we had in place were going to be a hit at ASCO,” says Eveo CEO and founder Olivier Zitoun, “but we didn’t expect the reaction to be as big as it was. The traffic in the booths was remarkable.”

Ensuring success at trade shows is no easy task. To maximize the potential for success, Eveo recommends following these simple best practices:

1. Start planning for the launch of new technologies early in the booth planning process. The more time you spend up front, the more smoothly everything will go.
2. Perform live technology testing for new programs as part of the booth planning and set up process. This is often overlooked, but an important key to success.
3. Train reps and booth personnel on new technologies prior to the show. Reps should be focused on demonstrating exciting new technologies, not learning them as they go.
4. Optimize booth staffing by utilizing reporting and tracking for all show displays.
5. Send post-conference surveys to customers and corporate participants to learn about what worked and what didn’t.
6. Make sure there are clear signs and directions for each display, especially if it is a new technology.
7. To maximize ROI, develop programs that reps can use in the field after the show or health care providers can access digitally and/or via mobile devices. 

To enlist Eveo’s help in your next tradeshow, contact [email protected]. For a full list of Eveo’s services, visit http://eveo.com/what-we-do/.

ABOUT EVEO
For innovative e-marketing strategies and powerful digital solutions, many of the world’s leading pharmaceutical, biotech and medical device companies depend on Eveo, a full-service independent digital healthcare agency headquartered in San Francisco. Founded in1999, Eveo is led by CEO Olivier Zitoun and a seasoned management team with extensive backgrounds in healthcare and interactive. Eveo’s core capabilities encompass all facets of digital marketing, as well as non-traditional web solutions, video production, 3D animation, tradeshow solutions, mobile applications, multi-touch experiences and more. The agency has a staff of over 150, with field offices in Chicago, New York, New Jersey and Philadelphia. Over the course of its ten years in business, Eveo has collected over 70 industry awards and in 2010 was named the #1 Independent Digital Healthcare Agency in the U.S. (based on 2010 Agency List ranking agencies by revenue). Eveo is redefining the e in e-marketing. Visit: www.eveo.com

ORLANDO, FL–(Marketwire – July 15, 2010) –  WellCity, Inc. (http://www.WellCity.com), a wellness-related social network and subsidiary of WellTek, Inc. (OTCBB: WTKN), today announced a strategic partnership with XOOMA Worldwide (http://www.XoomaWorldwide.com), a global network marketing company, in which the two companies have collaborated to bring more than 200,000 new users, cutting edge wellness products, a robust infrastructure and a major distribution system into WellCity. The agreement serves as a catalyst for both companies to carry out its rapid expansion plans.

As part of the relationship, XOOMA will provide exclusive support with product distribution and logistics, one of XOOMA’s strongest assets. The two companies also agreed to work on future product development together.

“Our collaboration with WellCity is about joining our global mission of Changing the Health of a Generation with a true innovator in social networking,” said Ron Howell, President and CEO of XOOMA Worldwide. “We believe that the combination of WellCity and XOOMA’s strengths will be incredibly attractive to our distributors as well as WellCity ‘residents.'”

Randy Lubinsky, Chairman and CEO of WellTek, noted, “XOOMA provides WellCity with an immediate global platform and 200,000 new ‘residents,’ exposing us to a much larger audience. It’s a global brand that people already recognize.” Lubinsky continued, “The superiority of XOOMA products is consistent with the Gold Standard of our other brands. Partnering with XOOMA is a natural progression to our tactical expansion initiative and integrates well into WellTek’s growing portfolio of trusted health, fitness and wellness brands.”

About XOOMA Worldwide
XOOMA Worldwide is a global network marketing company distributing cutting edge health and wellness products: including vitamins and minerals, functional health beverages and weight loss and skin care products to over 60 countries around the world. XOOMA’s Scientific Advisory Board provides education and guidance on health related topics and peer-reviewed scientifically supported nutritional applications for prevention and optimal health support.

About WellCity Incorporated
WellCity is a social utility where health- and wellness-minded ‘residents’ can closely commune with one another; receive support, information and encouragement from their ‘neighbors’ and from a league of leading professional experts; shop for health and wellness-oriented product and services; compete in WellCity’s proprietary 90-Day Wellness Challenge; and even enjoy income opportunities by leveraging their personal network. For more information on the Company, please visit www.WellCity.com.

About WellTek Incorporated
WellTek is a global health, fitness and wellness company that provides proven solutions to help address some of the world’s most pressing and costly health and wellness challenges. The Company owns and operates WellCity, Inc., a premiere wellness-related social utility that helps ‘residents’ live longer, feel better, look younger and enjoy life more as they age. The Company’s subsidiary, MedX Limited, manufactures, markets and distributes the most advanced medical exercise equipment to the medical and fitness markets. Through its wholly owned subsidiary Pure HealthyBack, Inc., WellTek is redefining healthcare delivery by providing health plans, self-insured employer groups, and consumers with a viable non-surgical, lower cost treatment for patients who are seeking lasting relief from chronic neck and back pain. For more information on the Company, please visit www.WellTekinc.com. 

Certain statements contained in this press release, which are not based on historical facts, are forward-looking statements as the term is defined in the Private Securities Litigation Reform Act of 1995, and are subject to substantial uncertainties and risks in part detailed in the respective Company’s Securities and Exchange Commission filings, that may cause actual results to materially differ from projections. Although the Company believes that its expectations are reasonable assumptions within the bounds of its knowledge of its businesses, expectations, representations and operations, there can be no assurance that actual results will not differ materially from their expectations. Important factors currently known to management that could cause actual results to differ materially from those in forward-looking statements include the Company’s ability to execute properly its business model, to raise additional capital to implement its continuing business model, the ability to attract and retain personnel — including highly qualified executives, management and operational personnel, ability to negotiate favorable future debt facilities and capital raises, and the inherent risk associated with a diversified business to achieve and maintain positive cash flow and net profitability. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this press release will, in fact, occur. 

SAUNDERSTOWN, RI–(Marketwire – July 15, 2010) –  The Federal government issued new rules Tuesday that will reward doctors and hospitals for the “meaningful use” of electronic health records, a top goal of President Obama. The rules significantly scale back proposed requirements that the health care industry had denounced as unrealistic.

What: subject matter expert: impact of new government standards for EHRs on small physician practices

Why: Doctors and hospitals could receive as much as $27 billion over the next 10 years to buy equipment to computerize patients’ medical records. A doctor can receive up to $44,000 under Medicare and $63,750 under Medicaid, while a hospital can receive millions of dollars, depending on its size

Who: Amazing Charts founder and CEO Dr. Jonathan Bertman, one of the nation’s leading experts on EHR/EMR systems and issues/trends impacting small and medium-sized physician practices.

Amazing Charts, due to its industry-leading usability and satisfaction ratings in multiple studies and $995 price tag is the EHR-of-choice for small practices (used by more than 3600 practices in the U.S. alone)

Click here to see all recent news from this company

BETHESDA, MD–(Marketwire – July 15, 2010) –  

*MEDIA NOTE: Study will be presented at the Washington State Convention Center on Saturday, July 17, at 7:30am.

Essential foot care by a podiatrist has now been statistically proven to reduce hospitalization and amputation in adults with diabetes, according to a first of its kind study conducted by Thomson Reuters. The study will be presented by Vickie R. Driver, MS, DPM, during the American Podiatric Medical Association’s (APMA) 98th Annual Scientific Meeting in Seattle, July 15-18, 2010. The presentation will highlight the dramatic impact that as few as one visit to a podiatrist can have on patients with diabetes.

The study, which was sponsored by APMA, examined records for more than 32,000 patients with diabetes, ages 18-64, and compared health and risk factors for those who had podiatry visits to those who did not. Researchers found that care by a podiatric physician (defined as at least one preventative, pre-ulcer visit) was associated with a nearly 29 percent lower risk of amputation and 24 percent lower risk of hospitalization. Diabetic foot complications are the leading cause of non-traumatic lower limb amputation in the U.S. 

“The results of this study undeniably support visits to a podiatrist being critical to a diabetes patient’s health and well being,” said APMA member Dr. Driver. “No longer can care by a podiatrist be considered optional for those with diabetes, and the earlier a podiatrist is included in the diabetes management team, the better quality of life for the patient and greater health-care cost savings for all involved. This study clearly allows us to understand both the clinical and economic value of a podiatrist, in the team approach to saving diabetic patients’ feet.”

The study was conducted using Thomson Reuters’ MarketScan Research Databases, which house fully integrated, de-identified health-care claims data extensively used by researchers to understand health economics and outcomes. Studies based on MarketScan data have been published in more than 130 peer-reviewed articles in the past five years.

Lead researcher Teresa Gibson, PhD, director of health outcomes research at Thomson Reuters said, “Using the MarketScan Databases, we statistically matched patients with diabetes and foot ulcers who had visited a podiatrist with like patients who had not. The analysis of the data indicates that patients who had seen a podiatrist in the year prior to the onset of a foot ulcer had significantly lower rates of any amputation and hospitalization than those who had not.”

For additional information on the study, visit www.apma.org/diabetesstudy.

Media interested in attending the presentation during the APMA 98^th Annual Scientific Meeting should contact Angela Berard at [email protected] or 301-861-9342.

Founded in 1912, the American Podiatric Medical Association (APMA) is the nation’s leading and recognized professional organization for doctors of podiatric medicine (DPMs). DPMs are podiatric physicians and surgeons, also known as podiatrists, qualified by their education, training and experience to diagnose and treat conditions affecting the foot, ankle and structures of the leg. The medical education and training of a DPM includes four years of undergraduate education, four years of graduate education at an accredited podiatric medical college and two or three years of hospital residency training. APMA has 53 state component locations across the United States and its territories, with a membership of close to 12,000 podiatrists. All practicing APMA members are licensed by the state in which they practice podiatric medicine. For more information, visit www.apma.org.

Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world’s most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs 55,000 people and operates in over 100 countries. For more information, go to www.thomsonreuters.com.

Click here to see all recent news from this company

SALT LAKE CITY, UT–(Marketwire – July 15, 2010) –   When Patrick Treend was a member of the Florida Marlins organization, he faced some pretty stiff competition as an up-and-coming pitcher. Now, he’s making a pitch to become the voice of our nation’s Child Care and Early Education insurance industry.

Treend, President of Security Planning & Insurance Corporation, which for more than 30 years has been one of the nation’s most-trusted insurance Agencies, has quickly become one of the most highly respected advocates in the child care industry. He oversees the day-to-day operations of the parent company’s two primary entities, Child Care Insurance Professionals and Charter School Insurance Professionals, the preferred choice for insurance in early education and child care.

“My general philosophy is to work as our client’s voice, their advocate,” says Treend. “We strive to get the most competitive rates and coverage without any allegiance to any one carrier. Generally speaking, child care and early education has very little competition, little to no national resources and no voice as it relates to insurance services. In most cases, people are taken advantage of because of the lack of competition and overall lack of insurance professionals that focus on this market.”

Due to his vast insight and expertise on the current trends within the child care industry, Treend is asked to speak at all of the regional conferences for the prestigious National Child Care Association (NCCA). He was recently in Atlanta to address his constituents on the state of the health care industry.

On the new legislation for Health Care Reform: “Under the new Health Care Reform Law, small businesses will find major changes to how they must provide health coverage and how much they must pay for it,” claims Treend. “I remain concerned that any advances under the new reform bill will be eroded by the unchecked rise of health care costs that were not adequately addressed in the legislation.”

Added Treend, “As it relates to Child Care and small businesses in general, it will have a huge impact for the smaller centers. The majority of the smaller centers cannot afford a traditional group plan and, if they could, the employee base cannot afford their employee portion. The only thing that the reform bill will do in the near future is make the process more confusing and costly.”

For Treend to be asked to voice his opinions has not been uncommon since making his pitch to the insurance industry in 2002. After quickly rising in ranks at Liberty Mutual Group and Zion’s Insurance Agency, Treend set his strike zone on child care and early education, revamping Security Planning & Insurance Corporation by making it the first insurance Agency of its kind to focus exclusively on providing packaged insurance to private and independent Charter Schools and Child Care Centers nationwide.

Child Care Insurance Professionals and, more recently, Charter School Insurance Professionals, are already considered ahead of their time and are the preferred choice for child care and charter schools looking for cost savings, favorable terms, targeted service and exceptional follow-through.

“Child Care and Charter Schools now have the convenience of dealing with one insurance Agency that handles all their policies, creating a significant cost savings. Our firm’s business model of targeted insurance programs and packages, particularly in the commercial child care industry, has taught us the value of market specificity. We believe focusing on a specific market niche enables us to provide targeted service and benefits that an individual school or an independent provider would not be able to access,” said Treend. 

For more information on Child Care Insurance Professionals and Charter School Insurance Professionals, visit their respective sites at www.ChildCareInsuranceProfessionals.com and www.CharterSchoolInsurancePros.com or call (888) 812-9992.

Click here to see all recent news from this company

DUERLE, BELGIUM–(Marketwire – July 15, 2010) – Remedent, Inc. (OTCBB: REMI), an
international company specializing in research, development, and
manufacturing of oral care and cosmetic dentistry products, reported
results for the final quarter and for the year ended March 31, 2010 (in US
Dollars).

Net sales in the fourth quarter decreased 27% to $2.5 million from $3.4
million in the same year ago quarter. The decrease in sales was due to non
recurring license fees of approx $1 million received from Denmat in the
fourth quarter ended March 31, 2009.

Loss from operations in the fourth quarter was a loss of $111,138 $(0.01)
per share as opposed to a loss of $1,079,063 $(0.05) in the same year-ago
quarter, based upon 20 million weighted average basic shares outstanding.

Net loss for the year ended March 31, 2010 was $2.4 million or $(0.12) per
share, as compared with a loss of $3.0 million or $(0.15) per share for the
year ended March 31, 2009.

Cash and cash equivalents totaled $614,000 at March 31, 2010 as opposed to
$1.8 million at March 31, 2009.

Management Commentary

“Our sales strategy of shifting from our previous wholesale sales (B2B)
model via a distributor to a direct retail model (B2C) is beginning to take
shape. Included in our net loss of $111,000 for the fourth and final
quarter ended March 31, 2010, was a loss of $550,000 directly attributable
to our subsidiary Sylphar. The improved results are attributable to the
inclusion for the first time of our Asian operations into our consolidated
financial statements together with the gain realized from the sale of First
Fit. Sales at all our Spa locations, namely in Beijing, Hong Kong, Taiwan
and in Europe continue to exceed our expectations as sales continue to
climb during the first quarter of the next financial year,” said Guy De
Vresse the CEO of Remedent.

Conference Call Information

Remedent will host a conference call on July 20, 2010 at 11:00 a.m. Eastern
Standard time (8:00 a.m. Pacific time) to discuss these results and its
strategic plans for the future. A question and answer session will follow
management’s presentation. To participate in the call, dial the appropriate
number 5-10 minutes prior to the start time.

Date: Tuesday,  July 20,2010
Time 11:00 a.m. Eastern time (8:00 a.m. Pacific time).
Dial in number: 1-888-677-8749
International: 1-913-312-1482

A simultaneous web cast and replay of the call will be available through
July 31, 2010. The replay pass code is 8101477.

About Remedent

Remedent, Inc. specializes in the research, development, manufacturing and
marketing of oral care and cosmetic dentistry products. The company serves
professional dental industry with breakthrough technology for dental
veneers. These products are supported by a line of professional veneer
whitening and teeth sensitivity solutions. Headquartered in Belgium,
Remedent distributes its products to more than 35 countries worldwide. For
more information, go to www.remedent.com.

Statement under the Private Securities Litigation Reform Act of 1995

Statements in this press release that are “forward-looking statements” are
based on current expectations and assumptions that are subject to risks and
uncertainties. Such forward-looking statements involve known and unknown
risks, uncertainties and other unknown factors that could cause Remedent’s
actual operating results to be materially different from any historical
results or from any future results expressed or implied by such
forward-looking statements. In addition to statements that explicitly
describe these risks and uncertainties, readers are urged to consider
statements that contain terms such as “believes,” “belief,” “expects,”
“expect,” “intends,” “intend,” “anticipate,” “anticipates,” “plans,”
“plan,” “projects,” “project,” to be uncertain and forward-looking. Actual
results could differ materially because of factors such as Remedent’s
ability to achieve the synergies and value creation contemplated by the
proposed transaction. For further information regarding risks and
uncertainties associated with Remedent’s business, please refer to the risk
factors described in Remedent’s filings with the Securities and Exchange
Commission, including, but not limited to, its annual report on Form 10-K
and quarterly reports on Form 10-Q.

                      REMEDENT, INC. AND SUBSIDIARIES
                  CONSOLIDATED STATEMENTS OF OPERATIONS
                                (unaudited)



                           Three months ended            Year ended
                                March 31,                 March 31,
                            2010         2009         2010         2009
                        -----------  -----------  -----------  -----------
Net sales               $ 2,472,815  $ 3,390,355  $ 8,247,940  $14,639,541
Cost of sales               952,189    1,650,315    4,322,680    6,614,723
                        -----------  -----------  -----------  -----------
  Gross profit            1,520,626    1,740,040    3,925,260    8,024,818
                        -----------  -----------  -----------  -----------
Operating Expenses
Research and development     39,850       24,273      271,195      248,652
Sales and marketing         461,078      370,042    1,352,260    2,793,970
General and
 administrative           1,313,812    1,639,656    4,524,324    5,312,192
Depreciation and
 amortization               168,218      173,903      726,499      615,674
                        -----------  -----------  -----------  -----------
TOTAL OPERATING
 EXPENSES                 1,982,958    2,207,874    6,874,278    8,970,488
                        -----------  -----------  -----------  -----------
  OPERATING LOSS           (462,332)    (467,834)  (2,949,018)    (945,670)
                        -----------  -----------  -----------  -----------
NON-OPERATING (EXPENSE)
 INCOME 
Warrants issued pursuant
 to Distribution Agreement       --           --     (168,238)  (4,323,207)
Gain on disposition of OTC       --           --           --    2,830,953
IMDS provision                   --     (300,000)          --     (300,000)
Interest expense/other
 deductions                 (50,596)    (166,972)    (171,364)    (417,147)
Interest income/other
 income                      54,907        1,884      170,244      348,997
Other income                     --           --     (169,358)          --
                        -----------  -----------  -----------  -----------
TOTAL OTHER INCOME
 (EXPENSES)                   4,311     (465,088)    (168,238)  (1,860,404)
                        -----------  -----------  -----------  -----------

LOSS FROM CONTINUING
 OPERATIONS BEFORE
 INCOME TAXES              (458,021)    (932,922)  (3,118,376)  (2,806,074)
Income tax expense          (14,242)     (32,633)     (14,242)     (32,633)
                        -----------  -----------  -----------  -----------

NET LOSS FROM CONTINUING
 OPERATIONS BEFORE
 MINORITY INTEREST         (472,263)    (965,555)  (3,132,618)  (2,838,707)
NET (LOSS) INCOME
 ATTRIBUTABLE TO
 NON-CONTROLLING
 INTERESTS                 (346,683)     114,208     (782,703)     114,208
                        -----------  -----------  -----------  -----------

NET LOSS FROM CONTINUING
 OPERATIONS, ATTRIBUTABLE
 TO REMEDENT INC. COMMON
 STOCKHOLDERS           $  (111,138) $(1,079,763) $(2,349,915) $(2,952,915)
                        ===========  ===========  ===========  ===========

LOSS PER SHARE
Basic and fully diluted $     (0.01) $     (0.06) $     (0.12) $     (0.15)
                        ===========  ===========  ===========  ===========
WEIGHTED AVERAGE
 SHARES OUTSTANDING
Basic and fully
 diluted                 19,995,969   19,995,969   19,995,969   19,559,653
                        ===========  ===========  ===========  ===========

OTHER COMPREHENSIVE
 INCOME (LOSS):
Net loss attributable
 to Remedent, Inc.
 common stockholders    $  (111,138) $(1,079,763) $(2,349,915) $(2,952,915)
Foreign currency
 translation adjustment    (102,949)     (45,371)      (9,464)    (668,245)
                        -----------  -----------  -----------  -----------
Total other comprehensive
 loss                      (214,287)  (1,125,134)  (2,359,379)  (3,621,160)
Less: comprehensive
 (loss) income
 attributable to
 non-controlling
 interest                   (42,623)     (54,700)       7,130      (54,700)
                        -----------  -----------  -----------  -----------
COMPREHENSIVE LOSS
 ATTRIBUTABLE TO
 REMEDENT INC.,
 COMMON STOCKHOLDERS    $  (171,664) $(1,070,434) $(2,366,509) $(3,566,460)
                        ===========  ===========  ===========  ===========




                      REMEDENT, INC. AND SUBSIDIARIES
                        CONSOLIDATED BALANCE SHEETS


                                              March 31,2010  March 31,2009
                                              -------------  -------------
ASSETS
CURRENT ASSETS:
Cash and cash equivalents                     $     613,466  $   1,807,271
Accounts receivable, net of allowance for
 doubtful accounts of $65,845 at March 31,
 2010 and $33,966 at March 31, 2009                 806,931      3,208,120
Inventories, net                                  2,161,692      1,937,946
Prepaid expense                                     920,487      1,310,900
                                              -------------  -------------
Total current assets                              4,502,576      8,264,237
                                              -------------  -------------
PROPERTY AND EQUIPMENT, NET                       1,735,719      1,024,999
OTHER ASSETS
Long term investments and advances                  750,000        750,000
Patents, net                                        246,992        163,106
Goodwill                                            699,635             --
                                              -------------  -------------
Total assets                                  $   7,934,922  $  10,202,342
                                              =============  =============
LIABILITIES AND STOCKHOLDERS' EQUITY
 (DEFICIT)
CURRENT LIABILITIES:
Current portion, long term debt               $     215,489  $      78,798
Line of Credit                                      674,600        660,200
Accounts payable                                  1,932,684      1,398,420
Accrued liabilities                                 491,536      1,590,360
Due to related parties                              268,484             --
Income taxes payable                                     --         39,339
                                              -------------  -------------
Total current liabilities                         3,582,793      3,767,117
  Long term debt less current portion               425,882        100,542
                                              -------------  -------------
Total liabilities                                 4,008,675      3,867,659
                                              -------------  -------------

EQUITY:
Preferred Stock $0.001 par value (10,000,000
 shares authorized, none issued and
 outstanding)                                           --            --
Common stock, $0.001 par value; (50,000,000
 shares authorized, 19,995,969 shares issued
 and outstanding at March 31, 2010 and
 19,995,969 shares issued and outstanding at
 March 31, 2009)                                     19,996         19,996
Treasury stock, at cost; 723,000 and 723,000
 shares at March 31, 2010 and March 31, 2009
 respectively                                      (831,450)      (831,450)
  Additional paid-in capital                     24,742,201     24,106,055
Accumulated deficit                             (19,565,943)   (17,216,028)
Accumulated other comprehensive income (loss)
 (foreign currency translation adjustment)         (650,059)      (640,595)
Obligation to issue shares                           97,500             --
                                              -------------  -------------
Total Remedent, Inc. stockholders' equity         3,812,245      5,437,978
                                              -------------  -------------
Non-controlling interest                            114,002        896,705
                                              -------------  -------------
Total stockholders' equity                        3,926,247      6,334,683
                                              -------------  -------------
Total liabilities and equity                  $   7,934,922  $  10,202,342
                                              =============  =============

SPRING, TX–(Marketwire – July 15, 2010) –  Dallas-based developer The LaSalle Group, Inc. is breaking ground on its third specialized Alzheimer’s and Memory Care Assisted Living Community in the Houston area, Autumn Leaves of Cypresswood, in Spring, TX. Company leadership, principal investors and other key partners will gather to see the newest addition to the Autumn Leaves family at official ground breaking ceremonies Tuesday, July 20 beginning at 11:00 a.m. Ceremonies will take place at the Cypresswood site located at 6327 Cypresswood Drive in Spring, TX. Local media and Spring area officials are invited to attend as well. 

Research of the Houston area has continued to show a demand for dedicated Alzheimer’s beds that exceeds the current supply. “We will continue to develop in the Houston market,” said Mitchell Warren, President of The LaSalle Group. “Our partners and investors recognize the pent-up need for our dedicated services that cater to this specific population and based on our in-depth market research results, we are committed to continuing our growth pattern in this market.” Autumn Leaves of Cypresswood will be the 15th property developed by LaSalle over the past ten years. Currently, The LaSalle Group has nine Autumn Leaves communities operating successfully in the Dallas/Fort Worth market and three in the greater Chicago area. The first Houston property to open, Autumn Leaves of The Woodlands, is set to accept their first residents in August; construction on the second Houston property, Autumn Leaves of Riverstone, is underway in Missouri City and scheduled to be completed in early Spring 2011. The company plans to continue their current expansion into the Houston market opening new communities in the area over the next three years.

Autumn Leaves of Cypresswood is scheduled to be completed and accepting residents by late Spring 2011. The property will feature 38 units and accommodate approximately 46 residents. For more information on this or other LaSalle Group projects, contact the home office at (214) 239-8400.

Construction and Management
Lake Superior Contracting, LaSalle’s in-house, full-service construction division, will coordinate and manage the design and construction of the new property ensuring the distinctive, research-based structural design attributed to all of LaSalle’s Autumn Leaves communities is in place. Sister firm Constant Care Management Company will manage and oversee all of the day-to-day operations once the community opens.

About The LaSalle Group, Inc. 
Family-owned and operated, The LaSalle Group (with its subsidiaries and affiliates) develops, builds, manages and owns specialized assisted living residences for people with Alzheimer’s and other forms of memory impairment, as well as other specialized real estate properties throughout the United States. For more information about our business, companies and current projects visit http://www.LaSalleGroup.com or call 1-800-452-7255. “Our Family Caring For Your Family”

About Alzheimer’s Disease
Alzheimer’s disease is a fatal and progressive brain disease that affects over 5.3 million Americans. Currently there is no cure and medications do not stop or reverse the disease. As the most common form of dementia, it accounts for more than approximately 60% of dementia cases.

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – July 15, 2010) –  Healthnostics, Inc. (PINKSHEETS: HNSS), a medical manufacturing and biotechnology analytics company, has sold an interest in MedBioWeb, Corp., in exchange for 150 million shares of its common stock, thereby reducing the actual issued and outstanding shares of Healthnostics, Inc., to 155,857,509.

As the Company refocuses its business, it is contemplating the possibility of a sale of its remaining interest in MedBioWeb Corp. MedBioWeb Corp. may more readily achieve its profit goals as an independent company and Healthnostics, through its recent acquisition, may be more able to show a substantial increase in per share earnings due to the near halving of outstanding shares.

The Company will continue to pursue acquisitions that are both compatible and synergistic.

“The Company is witnessing dramatic changes, all of which we believe bode well for our stockholders. We are focusing on profitability and earnings per share, factors that will enhance our ability to thrive and grow,” said Alan Grofe, president.

About Healthnostics
Healthnostics, Inc. is a medical and biotechnology analytics company that provides comprehensive patient clinical monitoring and risk management systems to acute care hospitals and utilizes its Internet portals to deliver medical and biotechnology resource information to industry professionals as well as to the general public. Healthnostics’ major products include: Worldwide Wipes Co., a manufacturer and distributor of medical and other wipes, MedGuardian, a patient care monitoring and risk management system for hospitals that is fully Web-based; and through the MedBioWeb subsidiary, MedBioWorld™, one of the largest professional medical and biotechnology directory resource and reference portal sites on the Internet, and FamilyMedicalNet, a companion consumer healthcare information portal.
For further information please visit Healthnostics www.healthnostics.com, and Worldwide Wipes Co. www.wipesco.com, MedBioWorld www.medbioworld.com, and FamilyMedicalNet www.familymedicalnet.com.

And visit us on Facebook at www.facebook.com/Healthnostics.

This press release may contain certain statements that are not descriptions of historical information, but are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934. These forward-looking statements refer to matters that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated.

TUSTIN, CA–(Marketwire – July 15, 2010) –   Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today it has launched a new investor video channel on its corporate website (www.radient-pharma.com) to deliver regularly scheduled, dynamic video content to Wall Street and the investing community. The videos are also available at: http://radient.investorcandy.com/radient/RD#videos.

Investor communications through RPC’s new investor video channel will be delivered on a regular basis and will cover a broad range of topics and information, including personalized messages from RPC’s executive team, breaking company news, and in-depth updates on the Company’s business and product commercialization strategy, execution, timeline and progress. RPC also plans to leverage its online video channel as a medium to communicate to other key audiences beginning in the third quarter of 2010. Targeted audiences include distributors, strategic partners, oncologists, general practice physicians and cancer patients who may have used or are considering using RPC’s Onko-Sure in vitro diagnostic cancer test. 

“Video is becoming increasingly important as a way of reaching investors and business partners with valuable information,” commented RPC’s Chairman and CEO Mr. Douglas MacLellan. “RPC’s new Investor Video Channel is an excellent complement to our just launched corporate website and an excellent channel to communicate business activities that are of material importance our investing community.”

Updates on the availability of new content will be broadly communicated through the issuance of press releases. For additional information on RPC visit the Company’s website located at www.radient-pharma.com or contact RPC Investor Relations at 206.310.5323 or [email protected].

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is a pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic and therapeutic products, including the company’s Onko-Sure in vitro diagnostic (IVD) cancer test — a simple, non-invasive, patent-pending and regulatory-approved test used for the detection, screening, and monitoring of various types of cancer. Onko-Sure is approved by: the US FDA for the monitoring of colorectal cancer; Health Canada as a lung cancer screen and as a cancer monitoring tool; and as a cancer monitoring or cancer screening test in the European Union, India, Korea, and Taiwan. Visit www.Radient-Pharma.com for additional information.

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – July 15, 2010) –  (PINKSHEETS: SREH) — SREH CEO, Tony Dibiase, announces the official launch of the company’s website, www.SREHoldings.com, “toward overall branding, marketability, transparency and developing a strong corporate identity as a publicly traded holdings company. The site has been designed to provide easy access to information about SREH’s subsidiary companies, Mobile2Earth (www.mobile2earth.com) and Scientific News International (www.scientificnewsroom.com) both with a rich base of intellectual property as well as IP development internally and for clients,” states Dibiase.

www.SREHoldings.com is a clean interface for a user-friendly experience featuring company overviews, news, progress and updates. “The new website exemplifies the dynamism and scope of SREH and its subsidiaries. Serving as a home base, the website provides both existing and prospective clients and shareholders timely, quality information about SREH and its subsidiaries with links to each individual company’s website therein. Mobile2Earth and SNI are not exactly sexy companies, per se,” states Dibiase. “But therein lies a trademarked and 13 year industry tested news service, subscription based social networking, exclusive non-biased content for medical professionals, iPhone and iPad apps as members of the Apple Developer Connection, to start. They both feature highly unique, marketable IP that can lead to sexy growth and corporate expansion. The SREH website helps exhibit all that we do in an easily digestible form, with the individual company sites available for customers, clients and the like with branding in place, accordingly. Both companies feature robust capabilities and the new holdings page simplifies this and strengthens our brand all the while.”

The company has submitted current disclosure and financial documents with OTCMarkets and will announce an update in tier status once reflected on the site.

CUTTING EDGE MEDICAL MEETING NEWS EXCLUSIVELY AT Scientific News International! (www.scientificnewsroom.com) is SREH’s premiere all-in-one platform for medical conference and news information focusing on Cardiology, Gastroenterology, Hematology, Nephrology, Oncology, Primary Care, Rheumatology and Urology. The site is the web’s only online resource for medical professionals with access to the latest, cutting edge data presented at major medical meetings worldwide. Staffed by global medical writers, SNI reports the most current research and therapy findings directly. The site’s profitability is IP and subscription based without bias from any medical or pharmaceutical provider. 

In the beginning, there was…Fishing, Manga, global tide reports and more! Get your iphoneMobile2Earth (www.mobile2earth.com) app now. Choose from the iphone King James Bible, fishing reports worldwide, Japanese e-books and comics and so much more as Mobile2Earth unleashes phase 1 of its iphone app releases for mass consumption. 

Safe Harbor: This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

CAMBRIDGE, MA–(Marketwire – July 15, 2010) –  PharmaPros, a technical consulting and solutions provider specializing in data and workflow management for clinical trials, today announced that Medelis, a single-source provider for oncology drug development services, has selected PharmaPros’ recently launched eClinical OnDemand™ solution, a unique Software as a Service (SaaS) subscription model for data and technology management.

With eClinical OnDemand™, PharmaPros acts as an outsourced technology department providing all of the technology implementation, management, and support for an end-to-end eClinical suite, as a managed service accessible by the study, program, or as a functionally outsourced department. With this solution, small to mid-sized organizations gain the advantage of a seasoned technology team and best-in-class clinical technology suite delivered with the added value of Dataflow Manager, PharmaPros’ first-in-class study management solution. With Dataflow Manager as the solution’s central interface, study teams can collaborate on study management operations using real-time data intelligence, across systems, sources, and vendors.

“We are excited to have been selected by Medelis to provide this solution. PharmaPros has a unique domain expertise at the intersection of data and technology. This enables us to not only deliver the highest quality services, but to enable specialty service providers to focus on their core competencies and deliver innovative solutions,” said PharmaPros CEO, Peg Regan.

PharmaPros will provide additional services to support both EDC and paper based studies using their proprietary methodology: electronic Data Lifecycle Management (eDLM) in conjunction with Dataflow Manager. With the advantage of an integrated study workflow and access to in-stream study progress, Medelis and PharmaPros will work seamlessly throughout the trial to ensure the expected data lifecycle, trial milestones, and data availability are managed to expectation.

“We are pleased to have found this unique solution to extend our own service offerings. eClinical OnDemand™ has enabled us meet client requirements for progressive technology, in-stream study status and integrated data extracts on-demand, providing us a competitive advantage we would not have with other, more traditional outsourced solutions,” said Bob Bosserman, CEO of Medelis Inc.

PharmaPros’ eClinical OnDemand™ is the first solution of its kind in the industry. Providing small to midsize companies a fully integrated eClinical technology suite, supported by mission critical services to ensure data is managed and available on a continuum from start-up to analysis. Integrated data from all sources including sites, labs, and imaging centers are delivered through PharmaPros study management application Dataflow Manager, providing study teams an unparalleled view of study progress.

About PharmaPros Corporation
PharmaPros Corporation is a technical consulting and solutions provider specializing in data and technology for clinical trials. The company’s innovative approach and deep industry expertise, has resulted in the commercialization of a revolutionary solution that is redefining clinical trials management. The company’s premiere solution — Dataflow Manager™ — provides the ability to manage clinical trials using the most accurate and up-to-date information available, enabling trial sponsors and managers to make more rapid, and better-informed decisions during a trial. PharmaPros was formed in 1996, with headquarters in Cambridge, MA.

SOUTH SAN FRANCISCO, CA–(Marketwire – July 15, 2010) –   Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that the European Patent Office (EPO) has granted a European patent covering combinations of the Company’s lead drug candidate, voreloxin, with cytarabine. Cytarabine is the standard-of-care treatment for Acute Myeloid Leukemia (AML), and the therapy used in combination with voreloxin in a fully enrolled Phase 2 trial in patients with relapsed and/or refractory AML. Sunesis has also announced plans to initiate a multinational, randomized, double-blind, placebo-controlled, pivotal Phase 3 clinical trial of voreloxin in combination with cytarabine in a relapsed/refractory AML patient population in the second half of this year. European Patent No. 1 729 770 B1, titled “SNS-595 [voreloxin] and Methods of Using the Same,” following completion of the patent validation process, will provide patent coverage for such combination products in 30 member states of the European Patent Convention, including the major European markets, through 2025. Corresponding patent applications are pending in major markets throughout the world including Australia, Canada, Japan and the United States. 

“This patent is an important new addition to our intellectual property estate, as it covers the combination of voreloxin and cytarabine, the contemplated initial market application,” stated Daniel Swisher, Chief Executive Officer of Sunesis. “We are pursuing a sophisticated and deliberate strategy to provide exclusive coverage in the voreloxin patent estate out to 2030. Beyond our granted patents, we have filed patent applications covering formulations, combination uses, dosing, manufacturing processes and composition of matter claims. We look forward to the successful prosecution of these patent applications in multiple territories around the world.”

About Voreloxin

Voreloxin is a first-in-class anticancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis. Voreloxin is currently being evaluated in a fully enrolled single agent Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients and in a fully enrolled Phase 2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML. A Phase 2 single agent clinical trial in platinum-resistant ovarian cancer has also completed enrollment. Sunesis plans to initiate a multinational, randomized, double-blind, placebo-controlled, pivotal Phase 3 clinical trial of voreloxin in combination with cytarabine in a relapsed/refractory AML patient population in the second half of this year.

About Acute Myeloid Leukemia

AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The National Cancer Institute estimated that nearly 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. in 2009. Additionally, it is estimated that prevalence of AML is approximately 25,000 in the U.S. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. AML patients with relapsed or refractory disease and newly diagnosed AML patients over 60 years of age with poor prognostic risk factors typically die within one year, resulting in an acute need for new treatment options for these patients.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

This press release contains forward-looking statements, including without limitation statements related to the prosecution of patent applications and Sunesis’ plans to initiate a pivotal Phase 3 clinical trial of voreloxin in the second half of this year. Words such as “evaluate,” “planned,” “will,” “look forward” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis’ current expectations. Forward-looking statements involve risks and uncertainties. Sunesis’ actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include without limitation, risks related to Sunesis’ need for additional funding to fully finance the planned voreloxin pivotal trial, the risk that Sunesis’ development activities for voreloxin could be halted or significantly delayed for various reasons, the risk that Sunesis’ clinical studies for voreloxin may not demonstrate safety or efficacy or lead to regulatory approval, the risk that data to date and trends may not be predictive of future data or results, the risk that Sunesis’ nonclinical studies and clinical studies may not satisfy the requirements of the FDA or other regulatory agencies, risks related to the conduct of Sunesis’ clinical trials, risks related to the manufacturing of voreloxin, and the risk that Sunesis’ proprietary rights may not adequately protect voreloxin. These and other risk factors are discussed under “Risk Factors” and elsewhere in Sunesis’ Quarterly Report on Form 10-Q for the quarter ended March 31, 2010 and other filings with the Securities and Exchange Commission. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

MARKHAM, ONTARIO–(Marketwire – July 15, 2010) – Extendicare Real Estate Investment Trust (“Extendicare REIT” or the “REIT”) (TSX:EXE.UN) today announced that it has declared a cash distribution of C$0.07 per unit of the REIT (the “REIT Units”) for the month of July 2010, which is payable to unitholders of record at the close of business on July 30, 2010, and will be paid on August 16, 2010.

Extendicare Limited Partnership (the “Partnership”) also announced that it has declared a cash distribution of C$0.07 per Class B limited partnership unit (the “Exchangeable LP Units”) for the month of July 2010, which is payable to unitholders of record at the close of business on July 30, 2010, and will be paid on August 16, 2010.

The current annualized distribution rate of the REIT and Partnership is C$0.84 per unit, payable in monthly distributions of C$0.07 per unit. In accordance with the distribution policy of both the REIT and the Partnership, unitholders of record at the close of business on the last business day of each calendar month will be paid a distribution on or about the 15^th day of the following month.

Management estimates that approximately 70% of the 2010 distributions of the REIT and Partnership will be characterized as tax-deferred returns of capital for Canadian residents. To the extent the remaining 30% of distributions of the REIT and Extendicare LP to be made in 2010 are taxed as dividends, those paid to Canadian residents are eligible dividends as per the Income Tax Act (Canada). The REIT is not required to, and does not, calculate its “earnings and profits” pursuant to the United States Internal Revenue Code of 1986, as amended, and therefore no portion of its distributions represent qualified dividend income for U.S. tax purposes.

The REIT has a Distribution Reinvestment Plan, which provides Canadian resident holders of REIT Units and Exchangeable LP Units with the opportunity to increase their respective investments at a 3% discount to the volume weighted average trading price of the REIT Units on the TSX for the five trading days immediately preceding the distribution payment date. A copy of the Plan package is available under the investors section of the REIT’s website.

About Us

Extendicare REIT is a leading North American provider of long-term and short-term senior care services through its network of owned and operated health care centers. We employ 37,700 qualified and experienced individuals dedicated to helping people live better through a commitment to quality service that includes post-acute care, rehabilitative therapies and home health care services. Our 258 senior care centers in North America have capacity for approximately 28,900 residents. Extendicare REIT is a specified investment flow-through trust (SIFT) that has been subject to the SIFT tax since January 1, 2007.

Forward-looking Statements

Information provided by Extendicare REIT from time to time, including this release, contains or may contain forward-looking statements concerning anticipated financial events, results, circumstances, economic performance or expectations with respect to the REIT and its subsidiaries, including its business operations, business strategy, and financial condition. Forward-looking statements can be identified because they generally contain the words “expect”, “intend”, “anticipate”, “believe”, “estimate”, “project”, “plan” or “objective” or other similar expressions or the negative thereof. Forward-looking statements reflect management’s beliefs and assumptions and are based on information currently available, and the REIT assumes no obligation to update or revise any forward- looking statement, except as required by applicable securities laws. These statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the REIT to differ materially from those expressed or implied in the statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on the REIT’s forward-looking statements. Further information can be found in the disclosure documents filed by Extendicare REIT with the securities regulatory authorities, available at www.sedar.com and on the REIT’s website at www.extendicare.com.

PORT ST. LUCIE, FL–(Marketwire – July 15, 2010) –  RightSmile, Inc. (PINKSHEETS: RIGH) (www.RightSmile.com), the leader in Cosmetic Laser Teeth Whitening, continues to add more SmileShoppes across the country, while adding monthly reoccurring revenue at the same time. Furthermore, the Company will be reducing the current amount of shares outstanding by nearly 500 million shares within the coming days.

RIGH has been adding more SmileShoppes from the efforts of the independent rep groups recently signed up. Each SmileShoppe delivers monthly reoccurring revenue to the Company of approximately $500 per month, by just adding 10 new SmileShoppes per month at the end of a year the Company will have added $60,000 a month in additional revenue. The Company also has its first full time, in-house sales person, working from the corporate office in FL, and has been making good headway into the South Florida market.

The Officers of RIGH have decided to exchange their shares of Common stock for Preferred stock to ease investors’ minds that they may be selling their shares into the market. “Management is focused on building strong shareholder value and letting the shareholders know we are in it for the long haul,” stated Gene Caiazzo, President.

This reduction will reduce the Outstanding shares of the company’s Common stock to 550,000,000 from currently over 1 billion.

The Company has been working diligently on compiling and delivering all the information asked for by the audit team and looks forward to posting the audited financials on PinkSheets.

Once the financials are complete the company will hold its Annual Shareholders meeting this August in Fort Lauderdale, FL. As previously announced, all shareholders who attend the meeting can get their teeth whitened for free.

About RightSmile®:

Based in Port St. Lucie, Florida, RightSmile, Inc. engages in the distribution of branded and private label Cosmetic Laser Teeth Whitening products. Through Revodent, RIGH became a manufacturer of teeth whitening products. Revodent supplies numerous manufacturers/manu-packagers with components for teeth whitening solutions; in addition, they also supply final products designed for use in the dental, salon/retail and internet markets.

The Company believes all remarks made in the release to be accurate to the best of its knowledge.

The foregoing press announcement contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management’s expectations could be affected by, among other things, uncertainties relating to our success in completing acquisitions, financing our operations, entering into strategic partnerships, engaging management and other matters disclosed by us in our public filings from time to time. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Click here to see all recent news from this company

ONTARIO, CA–(Marketwire – July 15, 2010) – Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products is pleased to announce they are in the process of adding an additional prescription drug to their product line. This drug known as Fortex is used for the relief of pain and inflammation of musculoskeletal conditions such as arthritis and muscle soreness.

Fortex will be prescribed by orthopedic surgeons, rheumatologists, general practitioners and pharmacists throughout Canada. Under the terms of the exclusive license agreement, Axxess Pharma will have sole rights to manufacture and market the prescription drug in Canada. The Company anticipates this prescription drug will provide a significant source of residual revenue due to the continued increase of senior citizens and overworked population.

For more information, please contact Investor Relations at (973) 351-3868.

About Axxess Pharma, Inc.:

Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.

Safe Harbor

Statements about the Company’s future expectations and all other statements in this press release other than historical facts, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words “anticipate,” “estimate,” “expect,” “intend,” “plans,” “projects,” and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.